Home >> Oncology/Hematology >> Oncology/Hematology >> Baked Goods >> Technology & Media >>

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 102 | Code: MRS - 18276

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015’, provides an overview of the Pancreatic Ductal Adenocarcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pancreatic Ductal Adenocarcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pancreatic Ductal Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pancreatic Ductal Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pancreatic Ductal Adenocarcinoma Overview 8
Therapeutics Development 9
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview 9
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis 10
Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies 11
Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 13
Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Pancreatic Ductal Adenocarcinoma - Products under Development by Companies 16
Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes 17
Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development 18
Centrose Llc 18
Clovis Oncology, Inc. 19
F. Hoffmann-La Roche Ltd. 20
FibroGen, Inc. 21
Gilead Sciences, Inc. 22
Incuron, LLC 23
InvivoGen Therapeutics 24
Medisyn Technologies, Inc. 25
Merck & Co., Inc. 26
Nerviano Medical Sciences S.r.l. 27
OncoMed Pharmaceuticals, Inc. 28
Pfizer Inc. 29
SillaJen Co. Ltd. 30
Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
CBL-0137 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CYL-02 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
demcizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
EDC-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
FG-3019 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Hu-5F9G4 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ipafricept - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
JX-929 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MK-0752 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MK-8628 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
momelotinib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MRK-003 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MT-477 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NMSP-715 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PF-03084014 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PSL-001 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
RG-7787 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
rucaparib phosphate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SiG12D-LODER - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
vantictumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Pancreatic Ductal Adenocarcinoma - Recent Pipeline Updates 76
Pancreatic Ductal Adenocarcinoma - Dormant Projects 98
Pancreatic Ductal Adenocarcinoma - Discontinued Products 99
Pancreatic Ductal Adenocarcinoma - Product Development Milestones 100
Featured News & Press Releases 100
Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102

List of Tables
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2015 9
Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Pancreatic Ductal Adenocarcinoma - Pipeline by Centrose Llc, H1 2015 18
Pancreatic Ductal Adenocarcinoma - Pipeline by Clovis Oncology, Inc., H1 2015 19
Pancreatic Ductal Adenocarcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 20
Pancreatic Ductal Adenocarcinoma - Pipeline by FibroGen, Inc., H1 2015 21
Pancreatic Ductal Adenocarcinoma - Pipeline by Gilead Sciences, Inc., H1 2015 22
Pancreatic Ductal Adenocarcinoma - Pipeline by Incuron, LLC, H1 2015 23
Pancreatic Ductal Adenocarcinoma - Pipeline by InvivoGen Therapeutics, H1 2015 24
Pancreatic Ductal Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H1 2015 25
Pancreatic Ductal Adenocarcinoma - Pipeline by Merck & Co., Inc., H1 2015 26
Pancreatic Ductal Adenocarcinoma - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 27
Pancreatic Ductal Adenocarcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 28
Pancreatic Ductal Adenocarcinoma - Pipeline by Pfizer Inc., H1 2015 29
Pancreatic Ductal Adenocarcinoma - Pipeline by SillaJen Co. Ltd., H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Pancreatic Ductal Adenocarcinoma Therapeutics - Recent Pipeline Updates, H1 2015 76
Pancreatic Ductal Adenocarcinoma - Dormant Projects, H1 2015 98
Pancreatic Ductal Adenocarcinoma - Discontinued Products, H1 2015 99

List of Figures
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2015 9
Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Top 10 Targets, H1 2015 32
Number of Products by Stage and Top 10 Targets, H1 2015 32
Number of Products by Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Top 10 Routes of Administration, H1 2015 36
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37
Number of Products by Top 10 Molecule Types, H1 2015 38
Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing